Literature DB >> 22318289

Prostate cancer: PSA screening--more data, more debate.

Sarah Payton.   

Abstract

Entities:  

Year:  2012        PMID： 22318289     DOI： 10.1038/nrurol.2012.7

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506
  1 in total
  2 in total

1.  Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence.

Authors:  Roble G Bedolla; Jingjing Gong; Thomas J Prihoda; I-Tien Yeh; Ian M Thompson; Rita Ghosh; Addanki P Kumar
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 2.  Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention.

Authors:  Mark A Moyad; Nicholas J Vogelzang
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.